A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56
Purpose
This is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.
Conditions
- Wet Age Related Macular Degeneration
- wAMD
Eligibility
- Eligible Ages
- Over 50 Years
- Eligible Genders
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Previously treated or treatment naïve patients with a documented diagnosis of wAMD in the study eye, with onset of disease that began at any time prior to the Screening Visit. - Best Corrected Visual Acuity (BCVA) by Early Treatment Diabetic Retinopathy Study (ETDRS) letter score between 78 to 35 letters (approximately 20/32 to 20/200 Snellen equivalent) in the study eye at the Screening Visit and on Baseline (Day 1). - For previously-treated subjects, must have been treated with at least 2 anti-VEGF IVT injections (i.e., aflibercept 2 mg, aflibercept 8 mg, bevacizumab, ranibizumab, or faricimab) in the previous 6 months for wAMD per standard of care in the study eye prior to the Screening Visit.
Exclusion Criteria
- Subfoveal fibrosis, atrophy, or scarring in the center subfield. - BCVA using ETDRS charts <20 letters (20/400 Snellen equivalent) in the fellow eye.
Study Design
- Phase
- Phase 3
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel Assignment
- Primary Purpose
- Treatment
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Arm Groups
Arm | Description | Assigned Intervention |
---|---|---|
Experimental EYP-1901 2686 µg |
EYP-1901 |
|
Active Comparator Aflibercept |
|
Recruiting Locations
Phoenix, Arizona 85053
Springdale, Arkansas 72764
Bakersfield, California 93309
Beverly Hills, California 90211
Glendale, California 91203
Poway, California 92064
Redlands, California 92374
Sacramento, California 95841
Walnut Creek, California 94598
Whittier, California 95008
Denver, Colorado 80210
Fort Collins, Colorado 80528
Longmont, Colorado 80503
Danbury, Connecticut 06810
Greenwich, Connecticut 06830
Waterford, Connecticut 06385
Deerfield Beach, Florida 33064
Gainesville, Florida 32607
Lakeland, Florida 33805
Orlando, Florida 32806
Pensacola, Florida 32503
Pinellas Park, Florida 33782
Sarasota, Florida 34232
South Miami, Florida 33143
Tampa, Florida 33544
Tampa, Florida 33617
Winter Haven, Florida 33880
Marietta, Georgia 30060
Aiea, Hawaii 96701
Elmhurst, Illinois 60126
Lemont, Illinois 60439
Carmel, Indiana 46290
Lenexa, Kansas 66215
Portland, Maine 04101
Baltimore, Maryland 21209
Chevy Chase, Maryland 20815
Hagerstown, Maryland 21740
Towson, Maryland 21204
Boston, Massachusetts 02114
Springfield, Massachusetts 01107
Grand Blanc, Michigan 48439
Grand Rapids, Michigan 49546
Southaven, Mississippi 38671
St Louis, Missouri 63128
Reno, Nevada 89502
Teaneck, New Jersey 07666
Toms River, New Jersey 08755
Albuquerque, New Mexico 87109
Liverpool, New York 13088
Rochester, New York 14620
Slingerlands, New York 12159
Asheville, North Carolina 28803
Wilmington, North Carolina 28401
Winston Salem, North Carolina 27103
Tulsa, Oklahoma 74114
Eugene, Oregon 97401
Erie, Pennsylvania 16507
Kingston, Pennsylvania 18704
Charleston, South Carolina 29414
Florence, South Carolina 29169
Greenville, South Carolina 29605
Germantown, Tennessee 38138
Abilene, Texas 79606
Bellaire, Texas 77401
Bellaire, Texas 77401
Dallas, Texas 75231
Houston, Texas 77025
Plano, Texas 75075
San Antonio, Texas 78215
San Antonio, Texas 78240
Southlake, Texas 76092
The Woodlands, Texas 77384
Tyler, Texas 75703
Willow Park, Texas 76087
Salt Lake City, Utah 84107
Salt Lake City, Utah 84107
West Jordan, Utah 84088
Fairfax, Virginia 22031
Lynchburg, Virginia 24502
Winchester, Virginia 22601
Madison, Wisconsin 53705
More Details
- NCT ID
- NCT06668064
- Status
- Recruiting
- Sponsor
- EyePoint Pharmaceuticals, Inc.